Study Shows Cannabis Use During Pregnancy Doesn’t Affect Neurodevelopment of Children

July 14, 2023 · Cannabis Now

A new study has shown that cannabis use during pregnancy is not associated with differences in the neurodevelopment of children exposed to cannabis in the womb. The study, which was published last month in the peer-reviewed journal Paediatric and Perinatal Epidemiology last month, found that prenatal cannabis exposure was not associated with lower scores on neuropsychological tests in children or with autism among young adults.

“Prenatal marijuana exposure was not associated with secondary outcomes or risks of clinical deficit in any neuropsychological assessments,” the authors of the study wrote.

To conduct the study, researchers affiliated with Columbia University and the University of Western Australia, Perth used data on 2,868 children from the Raine Study, one of the world’s largest prospective cohorts of pregnancy, childhood, adolescence and adulthood, to analyze the progression of prenatal cannabis exposure from pregnancy through age 20. The children in the study underwent neuropsychological testing at age 10, and again as young adults aged 19 or 20.

The researchers designed the study to control for a wide range of clinical and sociodemographic factors that might affect the outcome of the results. The study was also conducted over a long time span, much longer than other studies that have attempted to investigate the potential outcomes of prenatal cannabis exposure. Because of the study’s characteristics and its robust sample size, the research helps provide a better idea of what prenatal cannabis exposure can do to unborn children.

With the study’s controls in place to account for confounding factors, the researchers found no association between exposure to cannabis in the womb and neurodevelopmental outcomes. Specifically, the authors of the study determined that prenatal exposure to marijuana “was not associated with worse neuropsychological test scores at age 10 or autistic traits at 19-20,” according to their conclusions.

The researchers noted limitations of their study, including changes in the average potency of cannabis products and evolving methods of ingesting the drug over the last few decades. The researchers studied children born between 1989 and 1992, meaning they were likely exposed to less potent cannabis than what is available today. The researchers noted that “further research is warranted in a more contemporary birth cohort with a range of neuropsychological outcomes to further elucidate the effect of prenatal marijuana exposure on neurodevelopment.”

Other Research Inconclusive

The results of previous studies investigating the effects of prenatal cannabis exposure have been inconsistent. Some studies have shown an increase in neurodevelopmental differences such as autism, ADHD and anxiety in children who were exposed to cannabis in the womb, while others have not revealed such associations.

systematic review of available research published in 2020 found that cannabis use during pregnancy may be associated with ADHD and related symptoms such as anxiety in children exposed to cannabis in utero. A separate study published the same year found that children whose mothers used cannabis while pregnant were 50% more likely to be diagnosed with autism. However, some experts note these studies may not be reliable because of limitations including problems with the methodology of the original research the studies are based on and small sample sizes.

Like the study published last month, other research has not found associations between prenatal cannabis exposure and neurodevelopmental problems in children.

2021 study found no association between cannabis exposure in the womb and autism when confounding factors such as the education of the mother and the use of alcohol and tobacco were controlled for. Another study published this year found that when maternal stress, a factor associated with both autism and cannabis use, was controlled for, no association between prenatal cannabis exposure and autism was found.

Expert Recommends Caution

Cannabis use during pregnancy is controversial, with many healthcare professionals warning that it should be avoided at all costs. Some cannabis advocates argue the dangers are overstated and that using cannabis during pregnancy can help relieve symptoms of morning sickness and alleviate stress, allowing pregnant women to get the nutrition and rest they need for a healthy pregnancy, among other benefits.

Dr. Peter Grinspoon, a primary care physician at Harvard Medical School and Massachusetts General Hospital and the author of “Seeing Through The Smoke: A Cannabis Specialist Untangles the Truth About Marijuana,” believes that there is still too much that is not known about how the drug can affect an unborn baby and cautions against cannabis use during pregnancy.

“It has not been conclusively demonstrated that cannabis is (or isn’t) safe during pregnancy or breastfeeding. As such, the prudent thing to do is to presume that cannabis use, especially regular, heavy cannabis use, is unsafe during pregnancy and breastfeeding until we uncover reasonable evidence that it is safe,” Grinspoon writes in the book. “Given what’s at stake, the burden of proof is on cannabis in this case. That means cannabis ought to be avoided or minimized by anyone who is pregnant or breastfeeding. Women who might become pregnant need to be carefully educated about the risks.” (Full Story)

In category:Research
Next Post

Gen Z Fuels Rise in Cannabis Over Alcohol

Cannabis continues to emerge as a substitute for alcohol among consumers, particularly for the Gen Z demographic, according to a report by data firm Brightfield Group. The findings show that an evolving social landscape and heightened health consciousness are influencing consumers to adjust…
Read
Previous Post

States give marijuana data to Biden administration for rescheduling review

At least five states with medical marijuana programs have shared key data – including the products patients are using and how they are affected – with U.S. health regulators as part of the Biden administration’s review of whether to remove…
Read
Random Post

Curaleaf Lays Off Hundreds of Workers Amid Slowdown

Cannabis giant Curaleaf Holdings Inc. (CSE: CURA) (OTCQX: CURLF) laid off around 220 of its employees ahead of the Thanksgiving holiday, Business Insider first reported. In a statement to the outlet, Curaleaf declined to say which department the cuts occurred within, though said…
Read
Random Post

Big California marijuana distributor Herbl collapses, brands left unpaid, sources say

Herbl, a major licensed California marijuana distribution company, is in receivership after falling behind on a key loan, a source close to the situation confirmed to MJBizDaily on Tuesday. The collapse of Herbl – which reportedly handled $700 million worth of product sales in…
Read
Random Post

Congressional Committee Schedules Hearing To Press FDA On Lack Of CBD Regulations Next Week As Bipartisan Lawmakers File Bills To Address The Issue

A congressional committee has scheduled a hearing for next week focused on the Food and Drug Administration’s (FDA) refusal to enact regulations to allow for the marketing of hemp-derived CBD products. And bipartisan and bicameral lawmakers have separately reintroduced a…
Read
Random Post

Philip Morris buying Israeli cannabis firm for up to $650M, report says

Multinational tobacco giant Philip Morris International is buying the Israeli cannabis tech firm Syqe Medical in a deal worth up to $650 million, according to the Israeli business newspaper Calcalist. Syqe’s chief product is a metered-dose pharmaceutical-grade inhaler that allows patients to…
Read